Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.
Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer. Cancer Lett. 2018 12 01; 438:86-96.